Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease
Abotsi, RE
; Nicol, MP; McHugh, G; Simms, V; Rehman, AM; Barthus, C; Ngwira, LG; Kwambana-Adams, B; Heyderman, RS; Odland, JØ; Ferrand, RA and Dube, FS
(2021).
Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease.
[Dataset].
Dryad.
https://doi.org/10.5061/dryad.5dv41ns71
; Nicol, MP; McHugh, G; Simms, V; Rehman, AM; Barthus, C; Ngwira, LG; Kwambana-Adams, B; Heyderman, RS; Odland, JØ; Ferrand, RA and Dube, FS
(2021).
Data from: The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease.
[Dataset].
Dryad.
https://doi.org/10.5061/dryad.5dv41ns71
Selection for resistance to azithromycin (AZM) and other antibiotics such as tetracyclines and lincosamides remains a concern with long-term AZM use for treatment of chronic lung diseases (CLD). We investigated the impact of 48 weeks of AZM on the carriage and antibiotic resistance of common respiratory bacteria among children with HIV-associated CLD.
Keywords
Streptococcus pneumoniae; Staphylococcus aureus; Haemophilus influenzae; Moraxella catarrhalis; children; Azithromycin; Antibiotic resistance; Antibiotic; Chronic lung disease; Africa; Zimbabwe; Malawi; Sputum; Nasopharyngeal swabs| Item Type | Dataset |
|---|---|
| Resource Type |
Resource Type Resource Description Dataset Quantitative |
| Capture method | Unknown |
| Date | 29 November 2021 |
| Language(s) of written materials | English |
| Creator(s) |
Abotsi, RE; Nicol, MP; McHugh, G; Simms, V; Rehman, AM; Barthus, C; Ngwira, LG; Kwambana-Adams, B; Heyderman, RS; Odland, JØ; Ferrand, RA and Dube, FS
|
| LSHTM Faculty/Department |
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology (-2023) Faculty of Infectious and Tropical Diseases > Dept of Clinical Research |
| Participating Institutions | London School of Hygiene & Tropical Medicine, London, United Kingdom |
| Date Deposited | 30 Nov 2021 10:25 |
| Last Modified | 16 Oct 2025 14:07 |
| Publisher | Dryad |
Explore Further
- Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial.
- Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial.
- Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease.
- Impact of Long-Term Azithromycin Therapy on Carriage and Resistance of Respiratory Bacteria Among Children with HIV-Associated Chronic Lung Disease: A Randomised Controlled Trial
No files available. Please consult associated links.
